Optimization of a method for determination of docetaxel sensitivity using prostate cancer organoids
https://doi.org/10.17650/1726-9776-2024-20-1-44-51
Abstract
Background. Analyzing the sensitivity of patient-derived tumor organoids to anti-cancer medications shows great potential for tailoring personalized treatment plans.
Aim. To obtain two prostate tumor organoid cultures, optimize the composition of culture medium, and to evaluate
the efficacy of the chemotherapeutic drug docetaxel using the obtained organoid cultures.
Materials and methods. The initial tissue was dissociated using the gentleMACS Octo homogenizer. The obtained cells were cultured in Matrigel with different culture media for selection of the optimal one. Cell viability and growth rates were assessed using the MTS assay.
Results. In this study, we successfully obtained two organoid cultures of prostate cancer cells and identified the most effective composition of culture medium. Using a cytotoxic test, it was shown that the obtained organoid cultures of prostate cancer cells had different sensitivity to docetaxel which was reflected in different inhibition of the tumor cell growth rate.
Conclusion. The utilization of prostate cancer organoids to determine the best treatment approach is a highly promising experimental technology. Nevertheless, additional research is required before integration of this technology into clinical practice.
Supporting agencies: The study was performed with the financial support from the Russian Science Foundation (Project No. 19-15-00397).
About the Authors
S. V. Nikulin
https://www.hse.ru/org/persons/357576526
National Medical Research Radiological Center, Ministry of Health of Russia; National Research University “Higher School of Economics”
Russian Federation
Competing Interests:
National Medical Research Radiological Center, Ministry of Health of Russia; National Research University “Higher School of Economics”
Russian Federation
Sergey V. Nikulin.
3 2nd Botkinskiy Proezd, Moscow 125284; 20 Myasnitskaya St., Moscow 101000
Competing Interests:
None
M. O. Silkina
National Research University “Higher School of Economics”
Russian Federation
Competing Interests:
Russian Federation
20 Myasnitskaya St., Moscow 101000
Competing Interests:
None
A. V. Razumovskaya
National Research University “Higher School of Economics”
Russian Federation
Competing Interests:
Russian Federation
20 Myasnitskaya St., Moscow 101000
Competing Interests:
None
M. P. Raygorodskaya
National Medical Research Radiological Center, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284
Competing Interests:
None
B. Ya. Alekseev
National Medical Research Radiological Center, Ministry of Health of Russia; Medical Institute of Continuing Education, Russian Biotechnological University
Russian Federation
Competing Interests:
Russian Federation
3 2nd Botkinskiy Proezd, Moscow 125284; 11 Volokolamskoe Shosse, Moscow 125080
Competing Interests:
None
References
1. Sung H., Ferlay J., Siegel R.L. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71(3):209–49. DOI: 10.3322/caac.21660
2. Malignant tumors in Russia in 2021 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2022. 252 p. (In Russ.).
3. Sandhu S., Moore C.M., Chiong E. et al. Prostate cancer. Lancet. 2021;398(10305):1075–90. DOI: 10.1016/S0140-6736(21)00950-8
4. Grimaldi A.M., Salvatore M., Cavaliere C. Diagnostic and prognostic significance of extracellular vesicles in prostate cancer drug resistance: A systematic review of the literature. Prostate Cancer Prostatic Dis 2023;26(2):228–39. DOI: 10.1038/s41391-022-00521-w
5. Bumbaca B., Li W. Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies. Acta Pharm Sin B 2018;8(4):518–29. DOI: 10.1016/j.apsb.2018.04.007
6. Liu J.M., Lin C.C., Liu K.L. et al. Second-line hormonal therapy for the management of metastatic castration-resistant prostate cancer: a real-world data study using a Claims database. Sci Rep 2020;10(1):4240. DOI: 10.1038/s41598-020-61235-4
7. Jackson S.E., Chester J.D. Personalised cancer medicine. Int J Cancer 2015;137(2):262–6. DOI: 10.1002/ijc.28940
8. Verduin M., Hoeben A., De Ruysscher D., Vooijs M. Patient-derived cancer organoids as predictors of treatment response. Front Oncol 2021;11:641980. DOI: 10.3389/fonc.2021.641980
9. Adamiecki R., Hryniewicz-Jankowska A., Ortiz M.A. et al. In vivo models for prostate cancer research. Cancers (Basel) 2022;14(21):5321. DOI: 10.3390/cancers14215321
10. Liston D.R., Davis M. Clinically relevant concentrations of anti-cancer drugs: a guide for nonclinical studies. Clin Cancer Res 2017;23(14):3489–98. DOI: 10.1158/1078-0432.CCR-16-3083
11. Xu H., Lyu X., Yi M. et al. Organoid technology and applications in cancer research. J Hematol Oncol 2018;11(1):116. DOI: 10.1186/s13045-018-0662-9
12. Rossi G., Manfrin A., Lutolf M.P. Progress and potential in organoid research. Nat Rev Genet 2018;19(11):671–87. DOI: 10.1038/s41576-018-0051-9
13. Byrne A.T., Alférez D.G., Amant F. et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer 2017;17(4):254–68. DOI: 10.1038/nrc.2016.140
14. Huang L., Bockorny B., Paul I. et al. PDX-derived organoids model in vivo drug response and secrete biomarkers. JCI Insight 2020;5(21):e135544. DOI: 10.1172/jci.insight.135544
15. Yoshida G.J. Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol 2020;13(1):4. DOI: 10.1186/s13045-019-0829-z
16. Xu H., Jiao D., Liu A., Wu K. Tumor organoids: applications in cancer modeling and potentials in precision medicine. J Hematol Oncol 2022;15(1):58. DOI: 10.1186/s13045-022-01278-4
17. Beshiri M., Agarwal S., Yin J.J., Kelly K. Prostate organoids: emerging experimental tools for translational research. J Clin Invest 2023;133(10):e169616. DOI: 10.1172/JCI169616
18. Nikulin S.V., Alekseev B.Ya., Sergeeva N.S. et al. Breast cancer organoid model allowed to reveal potentially beneficial combinations of 3,3’-diindolylmethane and chemotherapy drugs. Biochimie 2020;179:217–27. DOI: 10.1016/j.biochi.2020.10.007
19. Poloznikov A., Nikulin S., Bolotina L. et al. 9-ING-41, a small molecule inhibitor of GSK-3β, potentiates the effects of chemotherapy on colorectal cancer cells. Front Pharmacol 2021;12:1–18. DOI: 10.3389/fphar.2021.777114
20. Nikulin S.V., Alekseev B.Ya., Poloznikov A.A., Osipyants A.I. The first experience of using prostate cancer organoids as a model for personalized selection of drugs. Onkourologiya = Cancer Urology 2023;19(2):41–6. (In Russ.). DOI: 10.17650/1726-9776-2023-19-2-41-46
21. Hafner M., Niepel M., Chung M., Sorger P.K. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs. Nat Methods 2016;13(6):521–7. DOI: 10.1038/nmeth.3853
Review
For citations:
Nikulin S.V., Silkina M.O., Razumovskaya A.V., Raygorodskaya M.P., Alekseev B.Ya. Optimization of a method for determination of docetaxel sensitivity using prostate cancer organoids. Cancer Urology. 2024;20(1):44-51. (In Russ.) https://doi.org/10.17650/1726-9776-2024-20-1-44-51
Views:
307
Email this article 